M protein-based vaccines have been considered strong candidates, despite concerns over insufficient serotype coverage (N-terminal-based vaccines) and the association of M protein with the generation of cross-reactive antibodies linked to ARF and RHD (5). This evidence concerns the gene MYOM2 and rheumatic fever.